Louisiana 2019 Regular Session

Louisiana Senate Bill SCR16

Introduced
4/8/19  
Introduced
4/8/19  
Refer
4/9/19  
Report Pass
4/16/19  
Report Pass
4/16/19  
Passed
4/17/19  
Engrossed
4/17/19  
Engrossed
4/17/19  
Refer
4/22/19  
Refer
4/22/19  
Report Pass
5/15/19  

Caption

Requests the La. Department of Health to add Spinal Muscular Atrophy (SMA) to the state's newborn screening panel.

Impact

This resolution, if acted upon, would directly influence state health policy regarding newborn screenings. By adding SMA to the existing screening panel, Louisiana would align itself with several other states that have already recognized the necessity of screening for this condition. This proactive step is expected to improve health outcomes for infants diagnosed with SMA by facilitating early intervention, which can make a significant difference in managing the disease effectively.

Summary

Senate Concurrent Resolution No. 16 (SCR16) urges and requests the Louisiana Department of Health to take necessary actions to add Spinal Muscular Atrophy (SMA) to the state's newborn screening panel. SMA is a progressive and debilitating condition that primarily affects infants, leading to severe physical impairments and significantly impacting their quality of life. The resolution emphasizes the importance of early detection through genetic testing to ensure timely treatment and enhance survival rates for affected newborns.

Sentiment

The sentiment surrounding SCR16 is generally positive, reflecting a consensus on the need for increased awareness and proactive measures to combat SMA. Lawmakers, healthcare professionals, and advocacy groups have expressed support for the measure, highlighting its potential to save lives and improve the well-being of infants in the state. This reflects a growing recognition of the importance of early genetic screening as a vital component of infant healthcare.

Contention

While there appears to be overwhelming support for SCR16, potential points of contention could arise regarding the implementation of the resolution. Concerns may center around the logistical challenges and financial implications of expanding the newborn screening panel. Additionally, stakeholders may debate the prioritization of resources for screening compared to other emerging health issues. However, these discussions have not prominently featured in the documented proceedings thus far.

Companion Bills

No companion bills found.

Previously Filed As

LA HCR19

Requests the La. Department of Health to add Severe Combined Immunodeficiency to the state's newborn screening panel

LA HB07282

An Act Concerning Newborn Screening For Spinal Muscular Atrophy.

LA HCR33

Requests a study concerning potential inclusion in the state's newborn screening panel of all disorders listed on the federal Recommended Uniform Screening Panel

LA SCR3

Requests the Department of Health and Hospitals to submit a report by October 1, 2016, and to add Adrenoleukodystrophy (ALD) to the newborn screening panel no later than August 1, 2017.

LA HCR34

Provides for the potential addition of mucopolysaccharidosis type I and Pompe disease to the state's newborn screening panel

LA HB1102

To Create The Universal Newborn Screening Act; And To Ensure That Newborns Are Screened For Conditions Recommended By The United States Department Of Health And Human Services.

LA SCR17

Directs the Department of Health and Hospitals to evaluate and report on the health benefits and costs of adding Krabbe disease to the list of mandatory screenings performed on newborns under certain circumstances.

LA HB06919

An Act Requiring Newborn Screening For Duchenne Muscular Dystrophy.

LA HB05321

An Act Requiring Newborn Screening For Duchenne Muscular Dystrophy.

LA SB1020

Newborn screening; Duchenne muscular dystrophy

Similar Bills

No similar bills found.